Date: 2017-10-25
Type of information: Nomination
Compound: chief medical officer
Company: Gensight Biologics (France)
Therapeutic area: Rare diseases - Genetic diseases - Ophtalmological diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On October 25, 2017, GenSight Biologics announced
it has appointed Barrett Katz as chief medical officer, effective November 1, 2017. Dr. Katz replaces Mohamed Genead who resigned from the position for personal reasons. He brings extensive years of experience from both academic medicine and the industry as a neuroophthalmologist, including his most recent role as professor of ophthalmology, neurology and neurosurgery at Montefiore Medical Center and the Albert Einstein College of Medicine in New York.
- Dr. Katz will oversee clinical development and medical affairs at GenSight Biologics. He will be part of the executive committee and will report directly to Bernard Gilly, chief executive officer. Dr. Katz will be based in New York.
Financial terms:
Latest news:
Is general: Yes
